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Abstract
Background: Challenges exist in recruitment to trials involving interventions delivered by different clinical specialties.
Collaboration is required between clinical specialty and research teams. The aim of this study was to explore how
teamwork influences recruitment to a multicentre randomised controlled trial (RCT) involving interventions
delivered by different clinical specialties.
Methods: Semi-structured interviews were conducted in three centres with a purposeful sample of members of
the surgical, oncology and research teams recruiting to a feasibility RCT comparing definitive chemoradiotherapy
with chemoradiotherapy and surgery for oesophageal squamous cell carcinoma. Interviews explored factors
known to influence healthcare team effectiveness and were audio-recorded and thematically analysed. Sampling,
data collection and analysis were undertaken iteratively and concurrently.
Results: Twenty-one interviews were conducted. Factors that influenced how team working impacted upon trial
recruitment were centred on: (1) the multidisciplinary team (MDT) meeting, (2) leadership of the trial, and (3) the
recruitment process. The weekly MDT meeting was reported as central to successful recruitment and formed the
focus for creating a ‘study team’, bringing together clinical and research teams. Shared study leadership positively
influenced healthcare professionals’ willingness to participate. Interviewees perceived their clinical colleagues to
have strong treatment preferences which led to scepticism regarding whether the treatments were being
described to patients in a balanced manner.
Conclusions: This study has highlighted a number of aspects of team functioning that are important for
recruitment to RCTs that span different clinical specialties. Understanding these issues will aid the production of
guidance on team-relevant issues that should be considered in trial management and the development of
interventions that will facilitate teamwork and improve recruitment to these challenging RCTs.
Trial registration: International Standard Randomised Controlled Trial Number (ISRCTN): ISRCTN89052791.
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Background
Well-designed and well-conducted randomised con-
trolled trials (RCTs) generate robust evidence to inform
clinical and health-policy decision-making but many tri-
als face problems with recruitment [1–4]. The recruit-
ment process itself is often complex and involves several
linked activities performed by clinical and research staff
within and between different centres. Specific challenges
in the recruitment process occur where the trial involves
treatments routinely delivered by more than one clinical
specialty (e.g. oncology treatment versus surgery) [5, 6].
There may be several reasons why trials of treatments
delivered by more than one clinical specialty are difficult.
The practicalities and co-ordination of balanced infor-
mation provision for patients about both treatments can
be challenging. Whilst clinicians may be comfortable
explaining interventions they routinely deliver they may
well be less confident conveying the effectiveness of
treatments outside their specialist remit [7, 8]. The order
in which eligible patients routinely consult with different
clinical specialties within such trials may also have subtle
influences on patient treatment preferences and, there-
fore, enrolment. In addition there is a need for these
clinical teams to liaise closely with research professionals
conducting the trial. The interdependency and complex-
ity of components of the recruitment process means that
teamwork within and between clinical and research teams
is likely to be a factor in effective trial recruitment.
Multidisciplinary team (MDT) working within the de-
livery of cancer care is well-established and it is now
mandatory in many countries for management decisions
for all new patients with cancer to be made within
MDTs [9–14]. MDTs bring together healthcare profes-
sionals from many different backgrounds, such as sur-
geons, oncologists and specialist nurses who, as well as
agreeing to treatment strategies, share a responsibility
for recruiting patients to trials. MDTs have been sug-
gested as the ideal setting to help co-ordinate and maxi-
mise clinical trial recruitment but have to date not been
evaluated with regard to this outcome [15, 16].
The importance and benefits of teamwork within and
between clinical, multidisciplinary and research teams in
recruitment to trials with interventions delivered by
different clinical specialties is currently unknown. We
undertook qualitative research to explore these issues
within a multicentre feasibility trial in surgical oncology




This study was devised to explore the importance of
teamwork in recruitment to a multicentre study in sur-
gical oncology. The present study was nested within a
feasibility RCT that aimed to establish whether a full
trial comparing a surgical (oesophagostomy) with a
non-surgical treatment (definitive chemoradiotherapy)
for localised oesophageal squamous cell carcinoma
(SCC) was viable [17]. This trial was chosen as the set-
ting for the exploration of the role of teamwork in re-
cruitment because of the diverse nature of the two
interventions and because there were substantial varia-
tions in the number of patients successfully recruited
between participating centres. Ethical approval was ob-
tained for the present study and the feasibility study
from the North Somerset and South Bristol Research
and Ethics Committee (09/H0106/69).
Description of the trial recruitment pathway and teams
Eligible patients were offered separate consultations
with a member of the surgical team initially, and then
with a member of the oncology team, to discuss the
trial and treatment options. Centres recruited patients
to the trial for different lengths of time between April
2010 and March 2013. During this time, 375 patients
with oesophageal SCC were discussed in 331 MDT
meetings, and 42 (11 %) patients were considered eli-
gible. Of these, five patients were successfully rando-
mised, all from a single centre (centre 3) (Table 1).
We aimed to interview healthcare professionals who
participated in any aspect of recruitment to this study.
This included members of the surgical team (consultant
surgeons and specialist nurses), members of the oncology
team (consultant oncologists) and members of the re-
search team (research nurses, the chief investigator, the
principle investigators and clinical trials co-ordinators).
Data collection
Participants were purposively sampled to ensure that a
range of different healthcare professionals across all of
the study centres was included (Table 2). Interviewees in
centre 3 were known to SS but not to CW. Interviewees
in centres 1 and 2 were not known to either SS or CW.
Interviews in centre 3 were conducted by CW and in
centres 1 and 2 by SS. Interviews were conducted either
face-to-face or over the telephone between April 2012
and March 2013. All participants consented to being
interviewed. A semi-structured topic guide was devel-
oped from the literature on trial recruitment and
healthcare team effectiveness to explore perceptions of
teamwork and its role in recruitment to trials. The
topic guide was modified iteratively throughout the
study to reflect emergent findings (Appendix 1).
Data analysis
Interviews were audio-recorded and transcribed verba-
tim, with identifying details anonymised. Thematic ana-
lysis was undertaken using the constant comparison
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technique of grounded theory [18, 19]. This aims to gen-
erate new hypotheses about phenomena that are derived
or grounded in the data. Its central principle is of con-
stant comparison, where new findings are systematically
compared with existing data. In this way, similarities and
differences can be identified and emerging theories re-
fined through the ongoing assimilation of data. The
computer software package NVivo 10 was used to sup-
port data storage and analysis. Transcripts were coded
with key words or phrases and scrutinised for common
themes. Identified themes were compiled into a coding
frame, against which themes emerging from subsequent
transcripts were compared. Coding was carried out by
SS following initial double-coding with SP and inconsist-
encies were discussed and resolved with reference to the
raw data. Emergent themes were further discussed and
refined by consultation between SS, CW, SP, NM and
JD. SS was relatively new to qualitative research but was
well-supported by SP and NM, both of whom have a
wealth of qualitative research experience. CW is an ex-
perienced qualitative researcher. JD, who has extensive
qualitative research experience, oversaw the research.
Sampling, data collection and analysis were undertaken
iteratively and concurrently until data saturation, the
point at which no new themes occurred, was considered
to have been achieved.
Results
Participants
Twenty-four healthcare professionals were contacted via
email and sent a study protocol explaining the study and
asking them for an interview. Twenty-one responded, all
of whom were interviewed. This included eight surgeons
(including the chief investigator and a principle investi-
gator), five oncologists (including a principle investiga-
tor), five research nurses, a specialist upper gastro-
intestinal nurse, one research fellow, and the clinical tri-
als co-ordinator (Table 1). The mean length of interview
time was 30 min (range 10–53 min). Identified factors
that influenced how team working impacted upon trial
recruitment were centred on: the multidisciplinary team
meeting, leadership of the trial, and the recruitment
process. These themes are explained in the following
sections with illustrative quotes.
1. The multidisciplinary team meeting
Surgeons, oncologists and specialists nurses across all
centres described the weekly multidisciplinary team
meeting as an important factor in recruitment. The
MDT meeting was reported as an essential forum to
discuss the study in general, such as ensuring eligibility
criteria were clear and understood and also as an op-
portunity to ensure that all patients were screened for
eligibility and not missed:
P14: I think it’s (the MDT meeting) a very good
way of trying to get the information out that this trial
is occurring and we will discuss every patient that
comes through and it’s a very good way of flagging up
actually they’re potentially suitable for recruitment to
this trial. (Consultant surgeon, centre 3)
P2: I think (the MDT meeting) works well as a team,
and it’s partly that there is no way that a patient could
be missed so you can be absolutely sure that for this
sort of study all the patients get considered and that’s
the first step. (Consultant oncologist, centre 1)
Table 1 Number of patients who were discussed, found to be
eligible, and randomised at each centre
Centre 1 Centre 2 Centre 3
Patients with oesophageal SCC
discussed at MDT
162 50 163
Eligible for the pilot RCT 15 3 24
Randomised into pilot RCT 0 0 5
MDT multidisciplinary team, RCT randomised controlled trial, SCC squamous
cell carcinoma
Table 2 Participant profile
Study ID Centre Job title
P1 1 Consultant oncologist
P2 1 Consultant oncologist
P3 1 Research nurse
P4 1 Clinical trials co-ordinator
P5 1 Consultant surgeon, Principle investigator
P6 2 Consultant oncologist, Principle investigator
P7 2 Consultant oncologist
P8 2 Consultant surgeon
P9 2 Consultant surgeon
P10 2 Research nurse
P11 2 Research nurse
P12 3 Consultant surgeon
P13 3 Consultant surgeon
P14 3 Consultant surgeon
P15 3 Consultant surgeon
P16 3 Consultant surgeon, Chief investigator
P17 3 Consultant oncologist
P18 3 Research nurse
P19 3 Research nurse
P20 3 Research fellow
P21 3 Specialist UGI nurse
UGI Upper gastro-intestinal
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Structure of the MDT meeting
The structure of the multidisciplinary team meeting dif-
fered between sites and this was described as having an
important influence on teamwork and recruitment. In
centres 1 and 3, all healthcare professionals involved in
the study (surgeons, oncologists, specialist nurses and
research nurses) attended one central MDT meeting.
This appeared to reduce professional barriers as the
study was perceived as part of the MDT team’s responsi-
bility instead of the study team and clinical MDT team
being viewed as two separate entities. Decisions regard-
ing the eligibility of a patient were described as being
made by the MDT and not by any one individual. This
shared responsibility ensured ‘buy-in’ from all healthcare
professionals involved:
P17: We have a large trial portfolio and we try to
have ‘buy-in’ from the whole team to a clinical trial
so the clinical trials that we do are agreed by the
whole team then, not done in isolation. And the MDT
decision will be to offer a clinical trial. That’s one of
the reasons why we’ve been very successful in terms
of actually putting people into trials because there is
‘buy-in’ from the whole team to do clinical research.
So, I think it was an MDT decision that they were
eligible for the study and we went from there.
(Consultant oncologist, centre 3)
P14: No. I don’t see it as a surgical trial or an
oncological trial. I see it as a team trial. I see it as an
MDT trial. (Consultant surgeon, centre 3)
By contrast, in centre 2, rather than one central MDT
meeting, several smaller hospitals had their own MDT
meetings where patients with cancer were initially dis-
cussed. Any patients that were appropriate for poten-
tially curative treatment (and, therefore, eligible for the
study) were then also discussed at a central MDT
meeting attended by clinicians from these peripheral
hospitals. This occurred at another hospital location.
The peripheral MDT structure was described by all in-
terviewees in this centre as problematic. Each of the
peripheral sites acted as an individual team meaning
that there was not the same MDT ‘buy-in’ as was de-
scribed in centres 1 and 3, with communication limited
by institutional and specialty boundaries. Lack of inte-
gration of the research nurses into the multidisciplin-
ary team also appeared to be affected by this structure,
with interviewees suggesting that integration would
have been desirable and that the lack of it may have
been a factor affecting recruitment:
P6: We have evolved, um, into a team which has
maintained local routes, so we still have a system
where we have three local MDTs where we do the
diagnostics and the palliative treatments and then
they come together, the only time we all come
together is for potentially curative patients. By and
large patients are managed initially by local teams
and, therefore, for this study the big challenge was
when the patients are first diagnosed then seen by
a surgeon, the conversation evolves about what the
treatment options are. So, by the time we were having
the main decision around treatment, patients had
either missed consultations in terms of sort of getting
them recorded or they’d already evolved into whether
they were keen on surgery or not keen on surgery…
I’d have sort of six conversations with different teams
and you know making sure everybody was on board,
it was hard. (Consultant oncologist, centre 2)
P10: It would have helped to have surgical leadership at
the peripheral sites, we were separate, we needed
someone to lead the surgeons. If we had a research nurse
based in the peripheral hospital it would have brought
the two groups together. (Research nurse, centre 2)
P10: We are an independent oncology site – we
are not attached to the peripheral hospitals – so it
was very difficult to have any research nurses input
to support the surgeons. We were relying on the
nurse specialists, who were a little bit protective
and didn’t understand and had some fear about the
trial. Not having a research nurse based at the
peripheral sites was very difficult for them and the
surgeons needed the support. Research is alien to
the specialist nurses, they don’t understand about
research, obviously it’s a totally different role…
(They) were protective of their patients and fearful
of the study. (Research nurse, centre 2)
Length of time as a multidisciplinary team and involvement
with a RCT
The duration that clinical teams had worked together
as a multidisciplinary team within their centre was felt
to be a significant contributor to overall team function-
ing. Working with the same team members for a num-
ber of years was reported as increasing the efficiency of
the team. The timing of involvement in this RCT also
emerged as an important influence on teamwork, with
individuals who felt involved with the study from the
inception, and who perceived that they had participated
in influencing the design, describing more engagement
in the study (centre 1 and 3).
P17: So, I’ve been here for quite a few years now and
we’ve worked as a team for many years and that’s how
we’ve always worked and I think the team works quite
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successfully and has functioned quite well over many
years. (Consultant oncologist, centre 3)
P5: As a multidisciplinary team we had discussed
(the trial) for 14 months – a long time. All the team
knew that it was something we wanted to do.
(Consultant surgeon, centre 1)
P9: I think probably raising the awareness and bringing
the study to the forefront of people’s minds more often
was needed. Certainly I wasn’t really fully aware of what
the trial involved and what its aims and outcomes were
until I came to that meeting in (city)… after the trial
had started. (Consultant surgeon, centre 2)
2. Trial leadership
All informants initially described a single named leader
within their centre as having overall responsibility for all
aspects of the trial including ensuring that eligible pa-
tients were appropriately screened at the MDT meeting
and maintaining the profile of the study. In the only
centre to randomise patients (centre 3), views regarding
leadership appeared to change over the course of the
study, with the study becoming viewed less as being led
by an individual and more as a ‘team trial’, with all mem-
bers of the MDT having responsibility for delivery:
P12: (The trial) has raised the awareness within our
own MDT about the different options. It has stopped
being (name of individual’s) trial, which is what
it was called. There were the comments about
(name of individual’s) project or, you know (name
of individual’s) trial rather than the trial that we
were looking at. I don’t know whether (name of
individual’s) trial equalled pet project. That’s an
interpretation I took when certain individuals would
say it. I don’t know whether that was the case or
not because I’ve never challenged anybody on that
but that was an impression I got to begin with, um,
and I think it changed with time. (Consultant
surgeon, centre 3)
P17: No, I think – I hope the trial is owned by
the team. I mean (name of individual) is the chief
investigator, absolutely fine, but the concept of the
trial is owned by the team – doing the trial is owned
by the team not by an individual. The aim of clinical
research is to improve patient care in its generality
and, therefore, the whole team should have an
interest in it. Teams that are proactive in research
tend to have better quality outcomes as well. Fewer
complaints and better outcomes, so there are good
reasons for teams to be involved in research. If
individuals were involved in research that’s absolutely
fine, but it’s much more effective with ‘buy-in’ from
the whole team. (Consultant oncologist, centre 3)
In the other centres in which a single named person
continued to be viewed as the lead, the specialty of the
leader was reported as having an influence on team en-
gagement with the trial, with engagement being less
problematic if the leader and team members were from
the same speciality:
P1: I think we have very much a collaborative
approach and (name of consultant) leadership style is,
is very good, so he’s up there in the bow but the rest
of us are rowing quite happily behind. (Consultant
oncologist, centre 1)
P6: I guess then its about enthusiasm of the surgeons
to really take it on. It wasn’t their trial, you know they
weren’t against it but they probably weren’t as
proactive as I was to make it work.
3. The recruitment process
Treatment preferences
All interviewees believed that oncologists and surgeons,
who were responsible for describing the study interven-
tions, favoured a particular treatment. This resulted in
scepticism about whether the study treatments were
being described to patients with equal enthusiasm.
Preferences were described as subtle and not openly
expressed. Surgeons tended to believe that other sur-
geons favoured surgery and oncologists favoured che-
moradiotherapy. Oncologists also believed surgeons
favoured surgery:
P16: I don’t know whether fundamentally
(name of oncologist) thinks chemoradiotherapy’s a
better treatment. I have suspicions he does, but I’ve
no evidence for it. (Consultant surgeon, centre 3)
P7: I thought potentially, you know not all of them,
but some of the surgeons may have felt that
occasionally it was operable and that was preferable
treatment. (Consultant oncologist, centre 2)
P14: Some of my colleagues in the unit would want
to operate on absolutely everything they had the
opportunity to operate on, and so might not
emphasise the chemoradiotherapy bit quite as
strongly. (Consultant surgeon, centre 3)
P3: But of course the surgeon is obviously more
biased to surgery and the oncologist is biased to
that treatment. I think subconsciously the way they
talk to them… It may be something even more subtle
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than in words that they are saying. (Research nurse,
centre 1)
In view of these biases one interviewee suggested that
a member of the research team, as opposed to a surgeon
or oncologist, would be better placed to provide a bal-
anced description of the study and the involved treat-
ment arms:
P13: You almost want the patients informed and
consented and entered into the trial by a non-
oncologist and non-surgeons. You want somebody
who knows about both treatments, very well and in
detail, knows about potential complications but also
is removed from the frontline, so that they can impart
as much information as possible in an unbiased way.
(Consultant surgeon, centre 3)
The order in which patients had their treatment con-
sultations (either with a surgeon first and then an on-
cologist, or vice versa) was believed to also influence
treatment choices. Interviewees believed that patients
were developing strong treatment preferences in line
with the speciality of the clinician that they saw first
and, therefore, declining randomisation. Possible solu-
tions suggested to combat this bias included either chan-
ging the order in which they saw the specialists or to
have a single joint consultation in which a surgeon and
an oncologist both sit in the same consultation and ex-
plain the treatments to the patient:
P2: Well, certainly that’s our experience here,
particularly with the way that we did the consultations
is that they saw surgeons first and then oncologists.
They would often come to me as the oncologist and
say – you know I’ve already made my mind up – and
they usually wanted surgery but it might be that they
wanted radiotherapy. By the time they see the second
clinician they already have quite firm views about
which treatment they want. The other suggestion
was that maybe we could be seeing the patients in a
different order altogether or in a joint clinic. I think
that would be interesting as then for everything the
surgeon says the oncologist can give their opinion.
You could sort of act as a double act to give the
arguments for and against both mortalities of
treatment. (Consultant oncologist, centre 1)
P13: I think the main problem of the trial was who
saw them first. If the oncologist saw them first then
they would be able to lay out their stall first – with
the pluses and the minuses and then if they were seen
again – in a few days’ time by the surgeons then
foremost in their mind would be what the oncologist
had to offer and we (as surgeons) would then have to,
in inverted commas, compete with that. Whereas, if it
happened the other way round we would then at least
get our information across on a blank canvas. I think
that’s the difficult thing with two very different
treatments with two very different side-effect and
complication profiles. (Consultant surgeon, centre 3)
Discussion
This study has explored the importance of teamwork in
recruitment to a multicentre study in upper gastro-
intestinal cancer involving treatments delivered by dif-
ferent clinical specialties. The importance of the weekly
MDT meeting to establish patient eligibility and for
building a sense of a ‘team’ amongst the healthcare pro-
fessionals was emphasised by team members. Shared
leadership models across specialty and professional
boundaries appeared to motivate enthusiasm for the
study. Clinician bias towards the treatment routinely
offered by their specialty was perceived by all inter-
viewees. This led to scepticism about balanced informa-
tion provision to patients which was believed to have a
detrimental effect on recruitment rates. In light of these
findings, it is recommended that trials consider the
teams participating in recruitment and that future work
develops interventions to facilitate ‘trial teams’ that
span different clinical specialties.
A conceptual model known as ITEM (the Integrated
Team Effectiveness Model) has been developed by
Lemieux-Charles to aid the understanding of the effective-
ness of teams in healthcare [20]. This model depicts the in-
teractions between the task design, team process, and team
effectiveness. Whilst useful to begin building theories, the
authors acknowledge that more detailed and specific models
are in need of development for different types of healthcare
teams, such as those responsible for trial recruitment [20].
The value of the MDT meeting to trial recruitment has pre-
viously been described although these studies did not focus
on challenging trials of diverse interventions [15, 16, 21]. A
study examining MDT treatment recommendations at a
single specialist upper gastro-intestinal MDT meeting
showed that patients who were flagged up at the MDT
meeting as potentially eligible for a trial were significantly
more likely than those who were not to be screened for trial
entry by the clinical trials nurses and consequently enrolled
[16]. Shared decisions made in the context of the MDT
meeting attended by all members in the team responsible
for recruitment allows provision of a similar clinical mes-
sage from all involved in the patients’ cancer journey. This
is likely to enhance patients’ final understanding of clinical
equipoise and, therefore, likelihood of randomisation.
Shared decisions made by the MDT team regarding trial eli-
gibility may also reduce the anxiety encountered by some
healthcare professionals who feel a conflict between their
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role as advocate for the patient and recruiter [22]. This is
particularly important in trials involving interventions deliv-
ered by more than one specialty as detailed knowledge of
the interventions is required in order to decide that a pa-
tient would be suitable to undergo each of the treatments.
Interviewees in our study who had worked together
for longer periods of time (centres 1 and 3) were more
positive regarding the team’s perceived ability to recruit
into the study. This finding is in keeping with a survey
of 72 UK breast cancer teams which showed that the
length of time a team had worked together had a signifi-
cant influence on the ability to effectively co-ordinate
the service [23]. A novel RCT investigated the influence
of an educational intervention involving 22 cancer
MDTs in the UK aimed at improving the awareness, in-
volvement, communication, and recruitment rates to
clinical trials [24]. Attendance by teams at the focused
workshops improved several aspects of team functioning,
such as team members’ awareness of their colleagues’ roles
in regard to trial recruitment and time to develop specific
recruitment strategies that work for the entire team as op-
posed to individual groups. However, this intervention
failed to show a significant impact on the total number of
patients approached regarding trial entry.
Whilst other studies have examined individual clinicians’
reasons for choosing not to enter potentially eligible pa-
tients into a trial or the willingness to counter expressed
patient preferences, we are unable to find other published
literature that has explored perceptions regarding a col-
league’s treatment preferences [25, 26]. The majority of in-
terviewees in our study believed that surgeons and
oncologists had treatment preferences for the treatment
that they were responsible for delivering (surgery or chemo-
radiotherapy respectively). This led to suspicions regarding
whether the two treatments were being described to pa-
tients with equal enthusiasm. Perceived treatment prefer-
ences were not discussed between recruiters and appeared
to be considered inevitable. It is possible that holding joint
consultations in which the surgeon and oncologist sit to-
gether and explain the treatments and the study to the pa-
tient may reduce this problem or an independent research
nurse could be trained to explain both treatments to pa-
tients to reduce these problems and improve recruitment.
A nested study within the ProtecT trial (an RCT of treat-
ments for localised prostate cancer) randomised patients
to either a recruitment consultation with a consultant ur-
ologist or a research nurse, finding no significant differ-
ence in recruitment rates but a potential economic saving
associated with research nurses compared to consultant
surgeons undertaking the recruitment consultation [27].
Although this research is exploratory and novel, it is
potentially limited because only one randomised trial
has been studied and whether findings may be general-
ised to other settings requires further research. We did,
however, purposively select participants to interview to
achieve maximum variation within this study setting.
Another possible limitation is that the majority of the in-
terviews (centres 1 and 2) were conducted by a clinical
academic with a background in surgery which potentially
could have influenced the findings. To minimise this a
topic guide was followed, interviews were double-coded
and themes discussed between authors to ensure reli-
ability of the analysis. Interviews at centre 3 were also
conducted by a qualitative researcher who did not have
a surgical background, with similar findings emerging.
Triangulation of data would have also strengthened this
research. This could have been achieved by either under-
taking observations of the MDT meetings in order to dir-
ectly observe different team dynamics or interviewing
patients to explore the influences of teamwork on patients’
willingness to participate.
Conclusions
This qualitative study has highlighted a number of as-
pects of team functioning that are important for re-
cruitment to RCTs involving interventions delivered by
different clinical specialties. Ongoing work will con-
tinue to examine the specific aspects of task design and
team process that aid recruitment in other RCTs and




Oesophageal squamous cell cancer: induction chemo-
therapy and oesophagectomy versus induction chemo-
therapy and chemoradiotherapy – a feasibility study




2. Gain written consent (Consent Form 08)
3. Describe your title and role
Background
1. Tell me about your involvement in the recruitment to
trials, for example, the SCOPE trial. Probe for details.
2. Would you describe yourself as a scientist, clinician,
doctor/nurse, trialist, researcher, or…? Or do you have
more than one role? (If more than one role – are
these roles complementary or are there conflicts?)
3. Have you received any training as a recruiter or for
RCTs in general?
4. Tell me about your involvement in the recruitment
to the SCC feasibility/chemoradiotherapy trial.
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5. What is involved in the treatment arms of this trial?
6. When did recruitment start?
7. How well is recruitment going? Probe for details.
8. Do you think your colleagues (PIs and recruiters)
are ‘in equipoise’? Probe for details.
Recruitment pathway and teamwork
1. Are the eligibility criteria for the RCT clear? Do you
think PIs agree with them (and comply with them)?
2. Are there reasons why recruitment is/would be
difficult in this RCT, or have you had difficulties
with recruitment?
3. Would you say that you are ‘in equipoise’? What
does ‘equipoise’ mean to you?
4. How are patients recruited into this RCT, details
form screening to randomisation and who is
involved or mainly responsible for each step? Who
is involved with recruitment?
5. Who undertakes the assessment of patient
eligibility for this RCT? Are you involved in
eligibility assessment?
6. Who has lead this project, views about leadership?
7. Relationships and communication with other
members of multidisciplinary team, including the
research nurses?
8. Do you ever have a feeling during an appointment
that a patient should really have one treatment
rather than another? Probe: Why? What do you do
about that?
Difficulties during recruitment
1. What would you say are the main difficulties that
this trial faces with recruitment?
2. Is recruitment organised well? Do other people
explain the RCT to patients?
3. Are there difficulties with any particular arm?
4. Do patients have strong preferences?
5. Do you think this RCT is the right thing for these
patients?
Personal views
1. Do you think this RCT will be successful? Probe all
the reasons for answer.
2. Do you know (or have a hunch) about what the
outcome of the RCT will be?
3. If you were a patient in this position today, would
you agree to be recruited to the RCT and be
randomised? Or would you choose a treatment?
Which one?
Finally – improving recruitment
1. What might, in your opinion, improve the recruitment
appointments?
Close the interview
1. Record baseline information on the interviewee
(job, grade).
2. Thank the interviewee for participating in the
interview.
Abbreviations
MDT: multidisciplinary team; SCC: squamous cell carcinoma; UK: United
Kingdom.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SS, SP, NM, JD, and JB designed and executed the study and contributed to
the manuscript. The data were analysed by SS and CW. SS wrote the first
draft of the manuscript with contributions from all authors. All authors read
and approved the final manuscript.
Acknowledgements
We would like to acknowledge all clinicians who participated in this study
by agreeing to be interviewed. This article presents research commissioned
in part by the National Institute for Health Research (NIHR) under Research
for Patient Benefit Program PB-PG-0807–14131. The views expressed in this
publication are those of the author(s) and not necessarily those of the NHS,
the NIHR, or the Department of Health.
This work was undertaken with the support of the MRC ConDuCT-II Hub
(Collaboration and innovation for Difficult and Complex randomised con-
trolled Trials In Invasive procedures – MR/K025643/1)
Author details
1Centre for Surgical Research, School of Social and Community Medicine,
University of Bristol, Canynge Hall, 39 Whatley Road, BS8 2PS Bristol, UK.
2Division of Surgery, Head and Neck, University Hospitals Bristol NHS
Foundation Trust, Bristol, UK.
Received: 15 December 2015 Accepted: 14 April 2016
References
1. Barton S. Which clinical studies provide the best evidence? The best RCT
still trumps the best observational study. BMJ. 2000;321:255–6.
2. NHS Centre for Reviews and Dissemination. Systematic reviews of research
on effectiveness. In: Centre for Reviews and Dissemination’s guidance for
those carrying out or commissioning reviews: Report 4. 2nd ed. York:
University of York; 2001.
3. Puffer S, Torgerson D. Recruitment difficulties in randomised controlled
trials. Control Clin Trials. 2003;24(3S):S214–1.
4. Levato LC, Hill K, Hertert S, Hunninghake DB, Probstfield JL. Recruitment for
controlled trials: literature summary and annotated bibliography. Control
Clin Trials. 1997;18:328–57.
5. Donovan J, Mills N, Smith M, et al. Improving design and conduct of
randomised controlled trials by embedding the min qualitative research:
ProtecT (prostate testing for cancer and treatment) study. BMJ. 2002;325:766–70.
6. Paramasivan S, Huddart R, Hall E, Lewis R, Birtle A, Donovan J. Key issues in
recruitment to randomised controlled trials with very different interventions:
a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011).
Trials. 2011;15(12):78.
7. Jenkins VA, Fallowfield LJ, Souhami A, Sawtell M. How do doctors explain
randomised clinical trials to their patients? Eur J Cancer. 1999;35(8):1187–93.
8. McDaid C, Hodges Z, Fayter D, Stirk L, Eastwood A. Increasing participation
of cancer patients in randomised controlled trials: a systematic review.
Trials. 2006;7:16.
Strong et al. Trials  (2016) 17:212 Page 8 of 9
9. Department of Health. The NHS Cancer Plan. A plan for investment. A plan
for reform. London: DOH; 2000.
10. Tripathy D. Multidisciplinary care for breast cancer: barriers and solutions.
Breast J. 2003;9:60–3.
11. Luxford K, Rainbird K. Multidisciplinary care for women with breast cancer: a
national demonstration program. N S W Public Health Bull. 2001;12:277–79.
12. Zorbas H, Barraclough B, Rainbird K, et al. Multidisciplinary care for women
with early breast cancer in the Australian context: what does it mean? Med
J Aust. 2003;179:528–31.
13. Valdagni R, Salvioni R, Nicolai N, et al. In regard to Kagan: the multidisciplinary
clinic. Int J Radiat Oncol Bio Phys. 2005;61:967–8.
14. Van Nes J, van de Velde C. The multidisciplinary breast cancer team:
promoting better care. Ned Tijdschr Geneeskd. 2005;149:1929–31.
15. Twelves CJ, Thompson CS, Young J, Gould A. Entry into clinical trials in breast
cancer: the importance of specialist teams. Eur J Cancer. 1997;34(7):1004–7.
16. McNair AG, Choh CT, Metcalfe C, Littlejohns D, Barham CP, Hollowood A, et al.
Maximising recruitment into randomised controlled trials: the role of
multidisciplinary cancer teams. Eur J Cancer. 2008;44(17):2623–6.
17. Blazeby J, Strong S, Wilson C, Donovan J, Hollingworth W, Crosby T, et al.
Oesophageal squamous cell cancer: induction chemotherapy and
oesophagectomy versus induction chemotherapy and chemoradiotherapy – a
randomised feasibility study. BJC. 2014;15;111(2):234–40.
18. Glaser BG, Strauss A. The discovery of grounded theory: strategies for
qualitative research. Chicago: Aldine; 1967.
19. Seale C, Silverman D. Ensuring rigour in qualitative research. Eur J Public
Health. 1997;7(4):379–84.
20. Lemieux-Charles L, McGuire W. What do we know about health care team
effectiveness? A review of the literature. Med Care Res Rev. 2006;63(3):263–300.
21. Maslin-Prothero S. The role of the multidisciplinary team in recruiting to
cancer clinical trials. Eur J Cancer Care. 2006;15(2):146–54.
22. Donovan JL, Paramasivan S, de Salis I. Clear obstacles and hidden
challenges: understanding recruiter perspectives in six pragmatic
randomised controlled trials. Trials. 2014;6(15):5.
23. Catt S, Fallowfield L, Jenkins V, Langridge C, Cox A. The informational roles
and psychological health of members of 10 oncology multidisciplinary
teams in the UK. BJC. 2005;93:1092–7.
24. Jenkins VA, Farewell D, Farewell V, Batt L, Wagstaff J, Langridge C, et al.
Teams Talking Trials: results of an RCT to improve the communication of
cancer teams about treatment trials. Contemp Clin Trials. 2013;35:43–51.
25. Siminoff L, Zhang A, Colabianchi N, Saunders Strum C, Shen Q. Factors that
predict referral of breast cancer patients onto clinical trials by their surgeons
and medical oncologists. J Clin Oncol. 2000;18(6):1203–11.
26. Mills N, Donovan JL, Wade J, Hamdy FC, Neal DE, Lane JA. Exploring
treatment preferences facilitated recruitment to randomized controlled
trials. J Clin Epidemiol. 2011;64:10.
27. Donovan JL, Peters TJ, Noble S, Powell P, Gillatt D, Oliver SE, et al. Who can
best recruit to randomized trials? Randomized trial comparing surgeons and
nurses recruiting patients to a trial of treatments for localized prostate
cancer (the ProtecT study). J Clin Epidemiol. 2003;56(7):605–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Strong et al. Trials  (2016) 17:212 Page 9 of 9
